GT-MAB 2.5-GEX™ is a novel exceptionally potent anti-tumor specific antibody (GlycoBody) developed by GlycoDesign and GlycoOptimization, currently in clinical phase I:

• Indications: Colorectal, gastric, breast, kidney, liver, lung, prostate, pankreas and ovarian cancer & multiple myeloma
• Target: A new GlycoEpitope in combination with part of MUC1 (see figure)
• Format: Humanized & glycooptimized IgG1
• Modes of action: Very potent ADCC, apoptotic & phagocytosis mediated tumor cell killing
• Results of GlycoOptimization:
  • Fully human glycosylation
  • Manifold improvement of anti-tumor activity
  • Optimization of bioavailability

• Additional Highlights:
  • GlycoEpitope is very tumor specific
  • High affinity & number of binding sites
  • Very high specific accumulation in the tumor
  • Very potent anti-tumor activity in vitro and in vivo
  • Virtually no binding to human PBMCs
• Production cell line: GlycoExpress™
• Regulatory status: Phase I
  

Download GT-Mab 2.5 GEX Factsheet